anidulafungin has been researched along with Mycoses in 58 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (6.90) | 18.2507 |
| 2000's | 33 (56.90) | 29.6817 |
| 2010's | 17 (29.31) | 24.3611 |
| 2020's | 4 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Buitrago, MJ; Cuenca-Estrella, M; Gomez-Lopez, A; Mellado, E; Monzon, A; Rodriguez-Tudela, JL | 1 |
| Liu, W; Wang, S; Yuan, L | 1 |
| Baird, M; Hobbs, ALV; Martin, M | 1 |
| Cao, W; Lan, C; Liu, Y; Qin, S; Qin, Z; Zhang, P; Zhang, Z | 1 |
| Candoni, A; Facchin, G; Fanin, R; Lazzarotto, D | 1 |
| Bologna, R; Carnovale, S; Epelbaum, C; Escarra, F; Figueroa, C; Lede, R; Rosanova, MT; Sarkis, C; Sberna, N | 1 |
| Majumdar, S; Patil, A | 1 |
| Cai, WP; Chen, WS; Chen, XJ; He, Y; Hu, FY; Lei, HL; Li, LH; Song, WN; Tang, XP | 1 |
| Capilla, J; Fernández-Silva, F; Guarro, J; Hernández, P; Mayayo, E; Sutton, DA | 1 |
| Busuttil, RW; Limaye, AP; Meneses, K; Morris, MI; Pelletier, S; Safdar, N; Singh, N; Winston, DJ | 1 |
| Blijlevens, NM; Brüggemann, RJ; Burger, DM; Colbers, A; Donnelly, JP; Hol, S; Knibbe, CA; Van Der Velden, WJ | 1 |
| Bermúdez, A; Colorado, M; Conde, E; de Miguel, C; Ibarrondo, P; Insunza, A; López-Duarte, M; Richard, C; Yáñez, L | 1 |
| Jiang, Y; Jung, DS; Kontoyiannis, DP; Tverdek, FP | 1 |
| Peghin, M; Ruiz-Camps, I | 1 |
| Badali, H; Chowdhary, A; de Hoog, GS; Fakhim, H; Khodavaisy, S; Meis, JF | 1 |
| Katragkou, A; Roilides, E; Walsh, TJ | 1 |
| Cantón, E; Gobernado, M | 1 |
| Joseph, JM; Kim, R; Reboli, AC | 1 |
| Amodio, E; Barchiesi, F; Maida, CM; Milici, ME; Oliveri, S; Scalise, G; Spreghini, E; Trovato, L | 1 |
| Burhenne, H; Burkhardt, O; Kaever, V; Kielstein, JT | 1 |
| Cuenca-Estrella, M; Gurguí, M | 1 |
| Azanza, JR; Montejo, M | 1 |
| Gadea, I; Mensa, J | 1 |
| Lass-Flörl, C; Perkhofer, S | 1 |
| Balcer, HE; Chahine, EB; Sucher, AJ | 1 |
| Gullo, A | 1 |
| Borghi, E; Iatta, R; Montagna, MT; Morace, G | 1 |
| Menichetti, F | 1 |
| Kuti, EL; Kuti, JL | 1 |
| Böhmdorfer, M; Fuhrmann, V; Jäger, W; Leitner, JM; Meyer, B; Saria, K; Thalhammer, F; Zuba, C | 1 |
| Le Guyader, N; Leverger, G | 1 |
| Fortún, J | 1 |
| Aguado, JM; Blanes, M; Catalán, M; Len, O; Montejo, M; Moreno, A; Muñoz, P; Pozo, JC; Solé, A; Usetti, P; Varo, E | 1 |
| Drogari-Apiranthitou, M; Grammatikou, M; Kanioura, L; Mantopoulou, FD; Mitroussia-Ziouva, A; Petrikkos, G; Skiada, A; Tsakris, A; Vrioni, G | 1 |
| Gupta, AK; Tomas, E | 1 |
| Raasch, RH | 1 |
| Steinbach, WJ | 1 |
| Alexander, BD; Zaas, AK | 1 |
| Baker, CJ; Pannaraj, PS; Walsh, TJ | 1 |
| Benjamin, DK; Clark, K; Dowell, JA; Driscoll, T; Gonzalez, CE; Kilaru, R; Roden, MM; Schranz, J; Seibel, NL; Walsh, TJ | 1 |
| Morrison, VA | 1 |
| Sobel, JD; Vazquez, JA | 1 |
| Benjamin, DK; Cohen-Wolkowiez, M; Smith, PB; Steinbach, WJ | 1 |
| Morris, MI; Villmann, M | 1 |
| Cappelletty, D; Eiselstein-McKitrick, K | 1 |
| Khachikian, D; Kim, R; Reboli, AC | 1 |
| Green, MR; Greene, JN; Wetzstein, GA | 1 |
| Brielmaier, BD; Casabar, E; Kurtzeborn, CM; McKinnon, PS; Ritchie, DJ | 1 |
| Del Palacio, A; Pontón, J; Quindós, G | 1 |
| Catalán González, M; Montejo González, JC | 1 |
| Fortún Abete, J; Martín-Dávila, P | 1 |
| Balko, TV; Friesen, M; Harding, GA; Hoban, DJ; Kabani, A; Karlowsky, JA; Turik, M; Zelenitsky, SA; Zhanel, GG | 1 |
| Espinel-Ingroff, A | 1 |
| Baquero, F | 1 |
| Chiou, CC; Groll, AH; Walsh, TJ | 1 |
| de Pauw, B | 1 |
| Arathoon, EG | 1 |
32 review(s) available for anidulafungin and Mycoses
| Article | Year |
|---|---|
Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.
Topics: Antifungal Agents; Cell Wall; Drug Discovery; Fungi; GPI-Linked Proteins; Humans; Mannans; Mycoses; Triterpenes | 2020 |
Efficacy of anti-fungal agents for invasive fungal infection prophylaxis in liver transplant recipients: A network meta-analysis.
Topics: Anidulafungin; Antifungal Agents; Echinocandins; Fluconazole; Humans; Invasive Fungal Infections; Itraconazole; Liver Transplantation; Mycoses; Network Meta-Analysis; Randomized Controlled Trials as Topic; Transplant Recipients | 2022 |
Echinocandins in antifungal pharmacotherapy.
Topics: Anidulafungin; Animals; Antifungal Agents; Caspofungin; Drug Resistance, Fungal; Echinocandins; Humans; Lipopeptides; Micafungin; Mycoses | 2017 |
[Filamentous fungal infections in immunosuppressed patients: prophylaxis and treatment].
Topics: Anidulafungin; Antifungal Agents; Drug Combinations; Echinocandins; Fungi; Humans; Immunocompromised Host; Immunosuppression Therapy; Mycoses; Voriconazole | 2015 |
Role of Echinocandins in Fungal Biofilm-Related Disease: Vascular Catheter-Related Infections, Immunomodulation, and Mucosal Surfaces.
Topics: Anidulafungin; Animals; Antifungal Agents; Biofilms; Candida; Candidiasis; Catheter-Related Infections; Disease Models, Animal; Echinocandins; Fungi; Humans; Immunomodulation; Microbial Sensitivity Tests; Mucous Membrane; Mycoses | 2015 |
[Anidulafungin].
Topics: Anidulafungin; Animals; Antifungal Agents; Disease Models, Animal; Echinocandins; Humans; Mycoses | 2008 |
Anidulafungin: a drug evaluation of a new echinocandin.
Topics: Anidulafungin; Antifungal Agents; Clinical Trials as Topic; Drug Resistance, Fungal; Echinocandins; Esophagus; Fungemia; Humans; Mycoses; Oropharynx | 2008 |
[Current status of invasive fungal infections. New diagnostic techniques and antifungal agents].
Topics: Anidulafungin; Antifungal Agents; Aspergillosis; beta-Glucans; Candidiasis; Clinical Trials as Topic; Critical Care; Diabetes Complications; Disease Susceptibility; Echinocandins; Fungemia; Galactose; Hematologic Diseases; Humans; Immunocompromised Host; Mannans; Meta-Analysis as Topic; Mycoses; Neoplasms; Opportunistic Infections | 2008 |
[Pharmacokinetics and pharmacodynamics: interactions and adverse effects. Comparison with other echinocandins].
Topics: Aged; Anidulafungin; Antifungal Agents; Caspofungin; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug Monitoring; Echinocandins; Gastrointestinal Diseases; Half-Life; Humans; Immunosuppressive Agents; Lipopeptides; Liver; Liver Failure; Mycoses; Obesity; Renal Insufficiency; Tissue Distribution | 2008 |
[Potential of anidulafungin in combined therapy].
Topics: Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Azoles; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Echinocandins; Encephalomyelitis; Fungemia; Guinea Pigs; Humans; Lung Diseases, Fungal; Mice; Mycoses | 2008 |
Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.
Topics: Anidulafungin; Animals; Antifungal Agents; Clinical Trials, Phase III as Topic; Drug Combinations; Drug Synergism; Echinocandins; Humans; Molecular Structure; Mycoses; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2009 |
Echinocandins: the newest class of antifungals.
Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Child; Clinical Trials as Topic; Drug Resistance, Fungal; Echinocandins; Humans; Lipopeptides; Micafungin; Mycoses | 2009 |
Invasive fungal infections: the challenge continues.
Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Candida; Candidiasis; Drug Therapy, Combination; Echinocandins; Humans; Mycoses; Risk Factors | 2009 |
Anidulafungin, a new echinocandin: in vitro activity.
Topics: Anidulafungin; Animals; Antifungal Agents; Biofilms; Drug Resistance, Fungal; Echinocandins; Fungi; Humans; Mycoses | 2009 |
Anidulafungin, a new echinocandin: effectiveness and tolerability.
Topics: Anidulafungin; Animals; Antifungal Agents; Candidiasis; Echinocandins; Humans; Mycoses | 2009 |
Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.
Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Clinical Trials as Topic; Drug Interactions; Echinocandins; Humans; Mycoses | 2010 |
[Antifungal therapy update: new drugs and medical uses].
Topics: Anidulafungin; Antifungal Agents; Aspergillosis; Candidiasis; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Early Diagnosis; Echinocandins; Humans; Immunocompromised Host; Lipopeptides; Micafungin; Mycoses; Randomized Controlled Trials as Topic; Salvage Therapy; Treatment Outcome; Triazoles | 2011 |
New antifungal agents.
Topics: Administration, Oral; Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Caspofungin; Chemistry, Pharmaceutical; Drug Approval; Echinocandins; Humans; Lipopeptides; Macrolides; Mycoses; Peptides; Peptides, Cyclic; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 2003 |
Anidulafungin: review of a new echinocandin antifungal agent.
Topics: Anidulafungin; Animals; Antifungal Agents; Biotransformation; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Echinocandins; Fungi; Humans; Intestinal Absorption; Kidney Diseases; Liver Diseases; Mycoses; Peptides, Cyclic; Tissue Distribution | 2004 |
Antifungal agents in children.
Topics: Age Factors; Amphotericin B; Anidulafungin; Antifungal Agents; Caspofungin; Chemistry, Pharmaceutical; Child; Clinical Trials as Topic; Drug Approval; Drug Resistance, Fungal; Echinocandins; Fluconazole; Flucytosine; Humans; Itraconazole; Lipopeptides; Lipoproteins; Micafungin; Mycoses; Patient Selection; Pediatrics; Peptides, Cyclic; Pyrimidines; Safety; Thiazoles; Triazoles; United States; Voriconazole | 2005 |
Echinocandins: role in antifungal therapy, 2005.
Topics: Anidulafungin; Animals; Antifungal Agents; Caspofungin; Echinocandins; Fungal Proteins; Humans; Lipopeptides; Mycoses; Peptides, Cyclic | 2005 |
Echinocandin antifungals: review and update.
Topics: Anidulafungin; Animals; Antifungal Agents; beta-Glucans; Caspofungin; Echinocandins; Fungal Proteins; Humans; Lipopeptides; Lipoproteins; Micafungin; Mycoses; Peptides, Cyclic | 2006 |
Anidulafungin: a novel echinocandin.
Topics: Anidulafungin; Antifungal Agents; Echinocandins; Fungal Proteins; Humans; Mycoses; Peptides, Cyclic | 2006 |
Anidulafungin: a new echinocandin for the treatment of fungal infections.
Topics: Anidulafungin; Animals; Antifungal Agents; Drug Interactions; Echinocandins; Humans; Mycoses; Peptides, Cyclic; Randomized Controlled Trials as Topic | 2006 |
Echinocandins in the management of invasive fungal infections, Part 2.
Topics: Anidulafungin; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Catheterization; Critical Care; Drug Therapy, Combination; Echinocandins; Humans; Lipopeptides; Lipoproteins; Micafungin; Mycoses; Peptides, Cyclic; Transplants | 2006 |
The echinocandins.
Topics: Anidulafungin; Antifungal Agents; Aspergillus; Candida albicans; Caspofungin; Cryptococcus; Echinocandins; Fungal Proteins; Humans; Lipopeptides; Lipoproteins; Micafungin; Microbial Sensitivity Tests; Mycoses; Peptides, Cyclic | 2007 |
A comparative evaluation of properties and clinical efficacy of the echinocandins.
Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Caspofungin; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Echinocandins; Enzyme Inhibitors; Glucosyltransferases; Humans; Lipopeptides; Lipoproteins; Micafungin; Mycoses; Peptides, Cyclic; Treatment Outcome | 2007 |
[Anidulafungin: a new therapeutic approach in antifungal therapy. Pharmacology of anidulafungin].
Topics: Anidulafungin; Antifungal Agents; Echinocandins; Humans; Mycoses | 2008 |
[The role of anidulafungin therapy in solid organ transplant recipients].
Topics: Anidulafungin; Antifungal Agents; Echinocandins; Humans; Mycoses; Organ Transplantation; Postoperative Complications | 2008 |
New drugs and novel targets for treatment of invasive fungal infections in patients with cancer.
Topics: Anidulafungin; Antifungal Agents; Echinocandins; Humans; Immunocompromised Host; Lipopeptides; Lipoproteins; Micafungin; Mycoses; Neoplasms; Opportunistic Infections; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole | 2000 |
Is there a need for new antifungal agents?
Topics: Amphotericin B; Anidulafungin; Animals; Anti-Bacterial Agents; Antifungal Agents; Echinocandins; Fungal Proteins; Humans; Mycoses; Peptides; Peptides, Cyclic | 2000 |
Clinical efficacy of echinocandin antifungals.
Topics: Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Caspofungin; Echinocandins; Humans; Lipopeptides; Lipoproteins; Micafungin; Microbial Sensitivity Tests; Mycoses; Peptides; Peptides, Cyclic | 2001 |
2 trial(s) available for anidulafungin and Mycoses
| Article | Year |
|---|---|
Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients.
Topics: Adolescent; Adult; Aged; Anidulafungin; Antibiotic Prophylaxis; Antifungal Agents; Double-Blind Method; Echinocandins; Female; Fluconazole; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; Immunocompromised Host; Incidence; Liver Diseases; Liver Transplantation; Male; Middle Aged; Mycoses; Postoperative Complications; Prognosis; Risk Factors; Survival Rate; Transplant Recipients; United States; Young Adult | 2014 |
A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients.
Topics: Adolescent; Adult; Aged; Anidulafungin; Antifungal Agents; Blood Chemical Analysis; Chemoprevention; Echinocandins; Female; Humans; Immunocompromised Host; Male; Middle Aged; Models, Statistical; Mycoses; Young Adult | 2015 |
24 other study(ies) available for anidulafungin and Mycoses
| Article | Year |
|---|---|
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
Topics: Acremonium; Antifungal Agents; Aspergillus; Candida; Drug Resistance, Fungal; Echinocandins; Fungi; Humans; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Mycoses; Penicillium; Scedosporium; Spain | 2009 |
Successful treatment of disseminated Verruconis gallopava infection in a heart transplant recipient: A case report.
Topics: Anidulafungin; Antifungal Agents; Ascomycota; Heart Transplantation; Humans; Male; Middle Aged; Mycoses | 2022 |
18F-FDG Positron Emission Tomography (PET) Scan as a Useful Tool to Assess Response to Antimycotic Therapy in Disseminated Invasive Mycosis in Acute Myeloid Leukemia.
Topics: Aged; Anidulafungin; Antifungal Agents; Drug Combinations; Humans; Immunocompromised Host; Invasive Fungal Infections; Kidney; Leukemia, Myeloid, Acute; Liver; Male; Mycoses; Nitriles; Positron-Emission Tomography; Pyridines; Spleen; Treatment Outcome; Triazoles | 2020 |
Anidulafungin in children: Experience in a tertiary care children's hospital in Argentina.
Topics: Adolescent; Anidulafungin; Antifungal Agents; Argentina; Child; Child, Preschool; Echinocandins; Humans; Mycoses; Prospective Studies; Tertiary Care Centers; Tertiary Healthcare | 2017 |
Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Azoles; Echinocandins; HIV Infections; Humans; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Mycoses; Reagent Kits, Diagnostic; Talaromyces; Voriconazole | 2018 |
Evaluation of the efficacies of Amphotericin B, Posaconazole, Voriconazole, and Anidulafungin in a murine disseminated infection by the emerging opportunistic Fungus Sarocladium (Acremonium) kiliense.
Topics: Acremonium; Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Echinocandins; Male; Mice; Mycoses; Pyrimidines; Triazoles; Voriconazole | 2013 |
Experience with anidulafungin in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease.
Topics: Administration, Oral; Adult; Anidulafungin; Antifungal Agents; Drug Administration Schedule; Echinocandins; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Male; Middle Aged; Mycoses; Retrospective Studies; Transplantation, Homologous; Treatment Outcome | 2015 |
Switching to anidulafungin from caspofungin in cancer patients in the setting of liver dysfunction is associated with improvement of liver function tests.
Topics: Adult; Aged; Aged, 80 and over; Anidulafungin; Caspofungin; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Echinocandins; Female; Humans; Lipopeptides; Liver Function Tests; Male; Middle Aged; Mycoses; Neoplasms; Retrospective Studies; Young Adult | 2015 |
In Vitro Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of Phaeoacremonium.
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Ascomycota; Caspofungin; Echinocandins; Fluconazole; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Mycoses; Nitriles; Pyridines; Triazoles; Voriconazole | 2015 |
Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi.
Topics: Anidulafungin; Antifungal Agents; Echinocandins; Fungi; Humans; Microbial Sensitivity Tests; Mycoses | 2008 |
Extended daily dialysis does not affect the pharmacokinetics of anidulafungin.
Topics: Anidulafungin; Antifungal Agents; Contraindications; Echinocandins; Humans; Kidney Diseases; Mycoses; Renal Dialysis; Time Factors | 2009 |
Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration.
Topics: Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Chemoprevention; Echinocandins; Female; Hemofiltration; Humans; Infusions, Intravenous; Male; Middle Aged; Mycoses; Renal Insufficiency | 2011 |
[Echinocandins in children].
Topics: Anidulafungin; Antifungal Agents; Aspergillosis; Aspergillus; Candidiasis, Invasive; Caspofungin; Child; Echinocandins; Evidence-Based Medicine; Humans; Injections, Intravenous; Lipopeptides; Micafungin; Mycoses; Treatment Outcome | 2011 |
Safety of anidulafungin in solid organ transplant recipients.
Topics: Adult; Aged; Anidulafungin; Antifungal Agents; Echinocandins; Female; Follow-Up Studies; Graft Rejection; Heart Transplantation; Humans; Immunosuppressive Agents; Kidney Transplantation; Liver Transplantation; Lung Transplantation; Male; Middle Aged; Mycoses; Organ Transplantation; Postoperative Complications; Retrospective Studies; Young Adult | 2012 |
In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Drug Synergism; Echinocandins; Fungi; Humans; Microbial Sensitivity Tests; Mycoses; Triazoles | 2012 |
Advances in antifungal therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Animals; Antifungal Agents; Caspofungin; Child; Child, Preschool; Clinical Trials as Topic; Echinocandins; Fungal Proteins; Humans; Infant; Infant, Newborn; Lipopeptides; Lipoproteins; Micafungin; Middle Aged; Mycoses; Peptides, Cyclic; Pyrimidines; Thiazoles; Treatment Outcome; Triazoles; Voriconazole | 2005 |
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.
Topics: Adolescent; Anidulafungin; Antifungal Agents; Child; Child, Preschool; Echinocandins; Female; Humans; Male; Mycoses; Neutropenia; Peptides, Cyclic | 2006 |
Mould breakthrough in immunosuppressed adults receiving anidulafungin: a report of 2 cases.
Topics: Adult; Aged; Anidulafungin; Antifungal Agents; Echinocandins; Female; Hematologic Neoplasms; Humans; Immunocompromised Host; Male; Middle Aged; Mycoses; Superinfection | 2007 |
Early clinical experience with anidulafungin at a large tertiary care medical center.
Topics: Academic Medical Centers; Alanine Transaminase; Anidulafungin; Antifungal Agents; Aspartate Aminotransferases; Back Pain; Candida; Candidiasis; Drug Therapy, Combination; Echinocandins; Female; Humans; Male; Metronidazole; Missouri; Mycoses; Retrospective Studies; Time Factors; Treatment Outcome | 2008 |
[Anidulafungin in the invasive fungal infection: current topics].
Topics: Anidulafungin; Antifungal Agents; Echinocandins; Humans; Mycoses | 2008 |
In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.
Topics: Anidulafungin; Antifungal Agents; Aspergillus; Blastomyces; Candida; Cryptococcus neoformans; Echinocandins; Fungi; Humans; Microbial Sensitivity Tests; Mycoses; Peptides, Cyclic | 1997 |
Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
Topics: Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Caspofungin; Culture Media; Echinocandins; Fungi; Humans; Lipopeptides; Microbial Sensitivity Tests; Mycoses; Opportunistic Infections; Peptides; Peptides, Cyclic; Structure-Activity Relationship; Triazoles; Yeasts | 1998 |
[Antifungal drugs: the new frontier].
Topics: Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Candidiasis, Vulvovaginal; Caspofungin; Drug Resistance, Microbial; Echinocandins; Female; Fungi; Humans; Lipopeptides; Male; Mycoses; Peptides; Peptides, Cyclic; Pyrimidines; Research; Triazoles; Trypanocidal Agents; Voriconazole | 1998 |
LY 303366. ECB.
Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Candidiasis, Vulvovaginal; Drugs, Investigational; Echinocandins; Female; Fungi; Humans; Male; Mycoses; Peptides, Cyclic; Pneumocystis Infections; Rats | 1999 |